We are live on ! Find out more
LKFT

Lakefront Biotherapeutics American Depositary Shares
LKFT

Fund managers haven’t disclosed any holdings of LKFT yet.

LKFT Hedge Fund Activity: Q1 2026 in Review

90 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2026, worth a combined $938M — down 9% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new LKFT positions and 13 closed out — a net gain of 3 holders — while 33 added to existing stakes and 28 trimmed.

The largest buyer was Prosight Management, adding an estimated $15.8M. The largest seller was Millennium Management, cutting an estimated $7.66M.

  • 90 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $938M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2026, down 9% quarter-over-quarter.
  • 16 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2026 and 13 closed out, a net change of +3 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2026 was Prosight Management, an estimated $15.8M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2026 was Millennium Management, an estimated $7.66M sold.

Based on aggregated 13F filings for Q1 2026.